To Örebro University

oru.seÖrebro University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Variation in public health reimbursement policies of ECT and rTMS across 28 European countries: A call for evidence-based policy reform from the ECNP Neuromodulation Network
Department of Psychiatry and Neuroscience, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, Berlin, Germany; German Center for Mental Health (DZPG), Germany.
Human Neuroscience Group, Center for Neuroscience and Neuromodulation, Institute for Medical Research, University of Belgrade, Belgrade, Serbia.
Université Claude Bernard Lyon 1, CNRS, INSERM, Centre de Recherche en Neurosciences de Lyon (CRNL), Bron, France.
Pôle Hospitalo-Universitaire de Psychiatrie Adulte, Centre Hospitalier Guillaume Régnier, Rennes, France; Univ Rennes, Inria, CNRS, Inserm, IRISA UMR 6074, Empenn ERL U1228, Rennes, France; Centre d'Investigation Clinique de Rennes (CIC 1414 Inserm), Rennes, France; Université de Rennes, Rennes, France.
Show others and affiliations
2026 (English)In: Neuroscience applied, E-ISSN 2772-4085, Vol. 5, article id 107030Article in journal (Refereed) Published
Abstract [en]

Mental disorders contribute significantly to the disease burden in Europe. Brain stimulation treatments such as electroconvulsive therapy (ECT) and repetitive transcranial magnetic stimulation (rTMS) are supported by strong evidence and are recommended in clinical guidelines in many countries. However, access to these interventions remains highly inconsistent across Europe. Reimbursement by public health services plays a critical role in enabling equitable access to these therapies. In this study, we examined disparities in national reimbursement policies for ECT and rTMS for the treatment of mental disorders in both inpatient and outpatient settings across 28 European countries, leveraging information from public databases and expertise from a multinational expert group within the ECNP Neuromodulation Network. Our results show that ECT is reimbursed for inpatient care in all 28 studied countries, while outpatient ECT is reimbursed in 15 of 28 countries (53.6%), with a geographic trend toward higher availability in Scandinavian and Western European countries. rTMS reimbursement was reported in 15 of 28 countries (53.6%) for inpatient care and in 8 of 28 countries (28.6%) for outpatient care, with no consistent geographic pattern. Subsequent analyses examining reimbursement policies in relation to the national Human Development Index (HDI), the Gini coefficient, and healthcare infrastructure metrics revealed no statistically significant differences between countries that do and do not reimburse outpatient ECT. Although countries reimbursing outpatient ECT showed numerically fewer hospital beds and slightly higher HDI values, these differences did not reach statistical significance. Similarly, no significant associations were observed between rTMS reimbursement and indicators of socioeconomic development, income inequality, or healthcare infrastructure. These findings highlight a striking disparity in national reimbursement policies across Europe, despite the solid evidence base for ECT and rTMS in treating mental health disorders. The current landscape suggests that many patients in Europe experience limited access to these effective treatments that could alleviate individual suffering and reduce societal disease burden. We call for urgent policy action to align health system reimbursement with clinical evidence for treatment efficacy and to improve access to evidence-based brain stimulation therapies across Europe.

Place, publisher, year, edition, pages
Elsevier, 2026. Vol. 5, article id 107030
National Category
Psychiatry
Identifiers
URN: urn:nbn:se:oru:diva-131985DOI: 10.1016/j.nsa.2026.107030ISI: 001898436200001PubMedID: 42889627OAI: oai:DiVA.org:oru-131985DiVA, id: diva2:2111532
Funder
German Research Foundation (DFG), 565437584German Research Foundation (DFG), 571864092Wellcome trust, Z334349/Z/25/ZGerman Research Foundation (DFG), GRK2773/1-454245598
Note

Funding Agencies:

NO acknowledges research funding from the German Ministry for Education and Research (German Centre for Mental Health, DZPG, Projects JE2, JE5: 01EE2305A; Project Resolve-PCC: 01EQ2409F; Project FEDORA: 01EQ2403A) and the German Ministry for Health (Project REMIT: 2524FSB34A; Project MultiCare: 2524FSB62D). JR was supported by the LOEWE program of the Hessian Ministry of Science and Arts (Grant Number: LOEWE1/16/519/03/09.001(0009)/98). JR was funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) – 565437584 and 571864092.

This work was in part supported by funding from the Wellcome Trust to JR, NO, JB [Z334349/Z/25/Z].

JB receives institutional support from the Ministry of Science, Technological Development and Innovation of the Republic of Serbia (451-03-136/2025-03/200015), and is engaged in EU-funded project TWINNIBS (101059369). AGA is employed by the University of Coimbra under the FCT-Tenure programme (reference 2023.15623.TENURE.065), funded by the Portuguese Foundation for Science and Technology (FCT). The Center for Research in Neuropsychology and Cognitive and Behavioral Intervention (CINEICC), Faculty of Psychology and Educational Sciences, University of Coimbra, is funded by national funds through FCT – Fundação para a Ciência e a Tecnologia, I.P., under project UID/00730/2025 (https://doi.org/10.54499/UID/00730/2025). MS is supported by a doctoral research grant from FCT (project reference 2021.07006.BD; DOI identifier: https://doi.org/10.54499/2021.07006.BD). KR is supported by the NIHR EME programme [Efficacy and Mechanism Evaluation (EME) Programme/Better Methods, Better Research (BMBR) (NIHR130077), NIHR grant NIHR203684 and the NIHR Biomedical Research Centre: Maudsley (NIHR203318). KR is also supported by the Medical Research Council (MRC) grant (APP32868), Medical Research Foundation (MRF-176-0002-RG-FLOH-C0929), Rosetrees Foundation (3442198) and the Deutsche Forschungsgemeinschaft (DFG) GRK2773/1-454245598. COI KR has received consultancy fees from Supernus and NeuraxPharm and had a grant from TAKEDA pharmaceuticals for another project. The design, management, analysis and reporting of the study are independent of the funders. MK received funding from ERDF-Project Brain Dynamics, No. CZ.02.01.01/00/22_008/0004643 and the Charles University research program Cooperatio-Neurosciences. 

Available from: 2026-10-20 Created: 2026-10-20 Last updated: 2026-10-20Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMed

Authority records

Nordenskjöld, Axel

Search in DiVA

By author/editor
Nordenskjöld, Axel
By organisation
School of Medical Sciences
Psychiatry

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 21 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf